$HART breakout climb $2.20 Website http
Post# of 24
Posted On: 11/29/2015 11:28:46 AM
$HART breakout climb
$2.20
Website
Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company, develops and commercializes regenerated organs for human transplant. The company is developing the HART-Trachea, which includes a scaffold, the patients cells, and a bioreactor to restore the structure and/or function of a severely damaged trachea; and automated solid organ bioreactor that has the ability to seed cells on an organ scaffold and keep them sterile and healthy during the growth phase prior to transplant. Its pre-clinical stage products include human-sized synthetic scaffold prototypes for esophageal transplant. The company has a pre-clinical collaboration with Connecticut Children's Medical Center to develop a process for repairing or replacing the esophagus to treat life-threatening pediatric conditions, such as esophageal atresia.
Harvard Apparatus Regenerative Technology, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts
Shares Outstanding: 12.02M
Float: 11.79M
% Held by Insiders: 12.06%
% Held by Institutions: 22.00%
Headlines
(0)
(0)Harvard Apparatus Regenerative Technology, Inc. (HART) Stock Research Links
Scroll down for more posts ▼